A predicted MSLN amplification rate of 13% was seen for esophageal cancer (N = 185), which was mainly driven by the subset of esophageal adenocarcinomas with an MSLN amplification rate of 31% (N = 64). Here, MSLN is linked to esophageal adenocarcinoma.